Ronald Chow1,2,3, James Im4, Nicholas Chiu5, Leonard Chiu6, Rahul Aggarwal5, Jihui Lee7, Young-Geun Choi8, Elizabeth Horn Prsic2, Hyun Joon Shin3,9,10. 1. Yale School of Public Health, Yale University, New Haven, Connecticut, United States of America. 2. Yale New Haven Health, Yale School of Medicine, Yale University, New Haven, Connecticut, United States of America. 3. Hanyang Impact Science Research Center, Seoul, Korea. 4. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 5. Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, Massachusetts, United States of America. 6. Columbia University Vagelos College of Physicians and Surgeons, Columbia University, New York City, New York, United States of America. 7. Weill Cornell Medicine, New York, New York, United States of America. 8. Sookmyung Women's University, Seoul, Korea. 9. Lemuel Shattuck Hospital, Jamaica Plain, Massachusetts, United States of America. 10. Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Abstract
INTRODUCTION: Statins may reduce a cytokine storm, which has been hypothesized as a possible mechanism of severe COVID-19 pneumonia. The aim of this study was to conduct a systematic review and meta-analysis to report on adverse outcomes among COVID-19 patients by statin usage. METHODS: Literatures were searched from January 2019 to December 2020 to identify studies that reported the association between statin usage and adverse outcomes, including mortality, ICU admissions, and mechanical ventilation. Studies were meta-analyzed for mortality by the subgroups of ICU status and statin usage before and after COVID-19 hospitalization. Studies reporting an odds ratio (OR) and hazard ratio (HR) were analyzed separately. RESULTS: Thirteen cohorts, reporting on 110,078 patients, were included in this meta-analysis. Individuals who used statins before their COVID-19 hospitalization showed a similar risk of mortality, compared to those who did not use statins (HR 0.80, 95% CI: 0.50, 1.28; OR 0.62, 95% CI: 0.38, 1.03). Patients who were administered statins after their COVID-19 diagnosis were at a lower risk of mortality (HR 0.53, 95% CI: 0.46, 0.61; OR 0.57, 95% CI: 0.43, 0.75). The use of statins did not reduce the mortality of COVID-19 patients admitted to the ICU (OR 0.65; 95% CI: 0.26, 1.64). Among non-ICU patients, statin users were at a lower risk of mortality relative to non-statin users (HR 0.53, 95% CI: 0.46, 0.62; OR 0.64, 95% CI: 0.46, 0.88). CONCLUSION: Patients administered statins after COVID-19 diagnosis or non-ICU admitted patients were at lower risk of mortality relative to non-statin users.
INTRODUCTION: Statins may reduce a cytokine storm, which has been hypothesized as a possible mechanism of severe COVID-19 pneumonia. The aim of this study was to conduct a systematic review and meta-analysis to report on adverse outcomes among COVID-19patients by statin usage. METHODS: Literatures were searched from January 2019 to December 2020 to identify studies that reported the association between statin usage and adverse outcomes, including mortality, ICU admissions, and mechanical ventilation. Studies were meta-analyzed for mortality by the subgroups of ICU status and statin usage before and after COVID-19 hospitalization. Studies reporting an odds ratio (OR) and hazard ratio (HR) were analyzed separately. RESULTS: Thirteen cohorts, reporting on 110,078 patients, were included in this meta-analysis. Individuals who used statins before their COVID-19 hospitalization showed a similar risk of mortality, compared to those who did not use statins (HR 0.80, 95% CI: 0.50, 1.28; OR 0.62, 95% CI: 0.38, 1.03). Patients who were administered statins after their COVID-19 diagnosis were at a lower risk of mortality (HR 0.53, 95% CI: 0.46, 0.61; OR 0.57, 95% CI: 0.43, 0.75). The use of statins did not reduce the mortality of COVID-19patients admitted to the ICU (OR 0.65; 95% CI: 0.26, 1.64). Among non-ICU patients, statin users were at a lower risk of mortality relative to non-statin users (HR 0.53, 95% CI: 0.46, 0.62; OR 0.64, 95% CI: 0.46, 0.88). CONCLUSION:Patients administered statins after COVID-19 diagnosis or non-ICU admitted patients were at lower risk of mortality relative to non-statin users.
Authors: Eduardo Barge-Caballero; Pedro J Marcos-Rodríguez; Nieves Domenech-García; Germán Bou-Arévalo; Javier Cid-Fernández; Raquel Iglesias-Reinoso; Paula López-Vázquez; Javier Muñiz; José M Vázquez-Rodríguez; María G Crespo-Leiro Journal: Med Clin (Barc) Date: 2022-05-08 Impact factor: 3.200
Authors: Magdalena Jachymek; Aleksandra Cader; Michał Ptak; Wojciech Witkiewicz; Adam Grzegorz Szymański; Katarzyna Kotfis; Jarosław Kaźmierczak; Aleksandra Szylińska Journal: Int J Environ Res Public Health Date: 2022-01-19 Impact factor: 3.390
Authors: Stefania Angela Di Fusco; Antonella Spinelli; Lorenzo Castello; Edoardo Mocini; Michele Massimo Gulizia; Fabrizio Oliva; Domenico Gabrielli; Giuseppe Imperoli; Furio Colivicchi Journal: Int J Environ Res Public Health Date: 2021-11-12 Impact factor: 3.390
Authors: Iva Selke Krulichová; Gisbert W Selke; Marion Bennie; Mohammadhossein Hajiebrahimi; Fredrik Nyberg; Jurij Fürst; Kristina Garuolienė; Elisabetta Poluzzi; Juraj Slabý; Corinne Zara Yahni; Mattia Altini; Maria Pia Fantini; Václav Kočí; Stuart McTaggart; Caridad Pontes; Chiara Reno; Simona Rosa; Marta Turu Pedrola; Mitja Udovič; Björn Wettermark Journal: Pharmacoepidemiol Drug Saf Date: 2022-07-18 Impact factor: 2.732